Table 1.
Respondents’ use of various topical medications for patients with clinical scenario consistent with aqueous deficient DED (artificial tears excluded)
| Topical Medications | Never use | Rarely use | Sometimes | Frequently | Always use |
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Cyclosporine A, 0.05 %, ophthalmic emulsion (RESTASIS) (N = 105) | 22 (21) | 12 (11) | 21 (20) | 35 (33) | 15 (14) |
| Cyclosporine A, 0.1 %, ophthalmic emulsion (N = 93) | 49 (53) | 22 (24) | 15 (16) | 6 (6) | 1 (1) |
| diclofenac sodium 0.1 % (N = 97) | 63 (65) | 21 (22) | 12 (12) | 1 (1) | 0 (0) |
| prednisolone acetate 1 % (N = 96) | 39 (41) | 28 (29) | 20 (21) | 9 (9) | 0 (0) |
| fluorometholone 0.1 % (N = 99) | 22 (22) | 18 (18) | 34 (35) | 23 (23) | 2 (2) |
| Loteprednol etabonate 0.5 % (N = 99) | 28 (28) | 21 (21) | 18 (18) | 29 (30) | 3 (3) |
| Resolvin E1 (omega −3 FA) eye drop (N = 95) | 64 (67) | 7 (8) | 20 (21) | 4 (4) | 0 (0) |
| Diquafosol 3 % ophthalmic solution (N = 93) | 75 (81) | 10 (11) | 5 (5) | 3 (3) | 0 (0) |
| Tacrolimus 0.03 % ophthalmic emulsion (N = 94) | 60 (64) | 25 (27) | 7 (7) | 1 (1) | 1 (1) |
| Autologous serum eye drops (N = 97) | 30 (31) | 19 (19.5) | 27 (28) | 19 (19.5) | 2 (2) |
| Vitamin A eye drops (0.01 % all trans-retinoic acid) (N = 96) | 39 (41) | 27 (28) | 22 (23) | 7 (7) | 1 (1) |